{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:11:50Z","timestamp":1781493110740,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:00:00Z","timestamp":1542844800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12985-018-1094-4","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T06:38:28Z","timestamp":1542868708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of hepatitis C virus genotype 4 in the DAA era"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"Di Biagio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cenderello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,22]]},"reference":[{"key":"1094_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3851\/IMP3061","volume":"22","author":"A Arias","year":"2017","unstructured":"Arias A, Aguilera A, Soriano V, Ben\u00edtez-Guti\u00e9rrez L, Lled\u00f3 G, Navarro D, Trevi\u00f1o A, Otero E, Pe\u00f1a JM, Cuervas-Mons V, de Mendoza C. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22:307\u201312.","journal-title":"Antivir Ther"},{"key":"1094_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cmi.2016.05.027","volume":"22","author":"JE Arends","year":"2016","unstructured":"Arends JE, Kracht PA, Hoepelman AI. European study Group for Viral Hepatitis (ESGVH)2. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clin Microbiol Infect. 2016;22:846\u201352.","journal-title":"Clin Microbiol Infect"},{"key":"1094_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/apt.13633","volume":"43","author":"A Majumdar","year":"2016","unstructured":"Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276\u201392.","journal-title":"Aliment Pharmacol Ther"},{"key":"1094_CR4","doi-asserted-by":"publisher","first-page":"e000112","DOI":"10.1136\/bmjgast-2016-000112","volume":"3","author":"E Hathorn","year":"2016","unstructured":"Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol. 2016;3:e000112.","journal-title":"BMJ Open Gastroenterol"},{"issue":"Suppl 1","key":"1094_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(Suppl 1):45\u201357.","journal-title":"J Hepatol"},{"key":"1094_CR6","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1097\/MD.0000000000000204","volume":"93","author":"AE Abd Elrazek","year":"2014","unstructured":"Abd Elrazek AE, Bilasy SE, Elbanna AE, Elsherif AE. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis. Medicine (Baltimore). 2014;93:e204.","journal-title":"Medicine (Baltimore)."},{"key":"1094_CR7","doi-asserted-by":"publisher","first-page":"e0177402","DOI":"10.1371\/journal.pone.0177402","volume":"12","author":"A D'Arminio Monforte","year":"2017","unstructured":"D'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A. Puoti M; Icona Foundation and HepaIcona Study Group. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017;12:e0177402.","journal-title":"PLoS One."},{"key":"1094_CR8","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","volume":"62","author":"PJ Ruane","year":"2015","unstructured":"Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J of Hepatology. 2015;62:1040\u20136.","journal-title":"J of Hepatology"},{"key":"1094_CR9","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, JG MH, Agarwal K, Zeuzem S. ASTRAL-1 investigators. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"1094_CR10","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M. ASTRAL-4 investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med."},{"key":"1094_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","volume":"151","author":"EJ Gane","year":"2016","unstructured":"Gane EJ, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology. 2016;151:902\u20139.","journal-title":"Gastroenterology"},{"key":"1094_CR12","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourli\u00e8re","year":"2017","unstructured":"Bourli\u00e8re M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de L\u00e9dinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S. POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017;376:2134\u201346.","journal-title":"N Engl J Med."},{"key":"1094_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, Yun C, Massetto B, Brainard DM, McHutchison JG, Bourli\u00e8re M, Peck-Radosavljevic M, Manns M, Pol S. Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166:109\u201317.","journal-title":"Ann Intern Med"},{"key":"1094_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"A Kohli","year":"2015","unstructured":"Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-Centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049\u201354.","journal-title":"Lancet Infect Dis"},{"key":"1094_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/apt.13883","volume":"45","author":"M Buti","year":"2017","unstructured":"Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-G\u00f3mez M, Rodr\u00edguez FG, Pascasio JM, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W. Simeprevir in combination with sofosbuvir in treatment-na\u00efve and \u2013experienced patients with hepatitis C virus genotype 4 infection: a phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther. 2017;45:468\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"1094_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jvh.12625","volume":"24","author":"M El Raziky","year":"2017","unstructured":"El Raziky M, Gamil M, Ashour MK, Sameea EA, Doss W, Hamada Y, Van Dooren G, DeMasi R, Keim S, Lonjon-Domanec I, Hammad R, Hashim MS, Hassany M, Waked I. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-na\u00efve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. J Viral Hepat. 2017;24:102\u201310.","journal-title":"J Viral Hepat"},{"key":"1094_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B. Effectiveness of Elbasvir and Grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152:164\u201375.","journal-title":"Gastroenterology"},{"key":"1094_CR18","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502\u20139.","journal-title":"Lancet."},{"key":"1094_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S2468-1253(16)30002-4","volume":"1","author":"I Waked","year":"2016","unstructured":"Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATHE-II): a multicentre, phase 3, partly randomised open label trial. Lancet Gastroenterol Hepatol. 2016;1:36\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1094_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X H\u00e9zode Forns","year":"2017","unstructured":"H\u00e9zode Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1094_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"Tarik Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2017. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2017.09.027\n                    \n                   [Epub ahead of print].","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"1094_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ebiom.2017.05.011","volume":"21","author":"M Yakoot","year":"2017","unstructured":"Yakoot M, Abdo AM, Abdel-Rehim S, Helmy S. Response tailored protocol versus the fixed 12 weeks course of dual Sofosbuvir\/Daclatasvir treatment in Egyptian patients with chronic hepatitis C Genotype-4 infection: a randomized, open-label. Non-inferiorityTrial EBioMedicine. 2017;21:182\u20137.","journal-title":"Non-inferiorityTrial EBioMedicine"},{"key":"1094_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/apt.14482","volume":"47","author":"H El-Khayat","year":"2018","unstructured":"El-Khayat H, Fouad Y, Mohamed HI, El-Amin H, Kamal EM, Maher M, Risk A. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018;47:674\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1094_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/jvh.12567","volume":"23","author":"SB Willemse","year":"2016","unstructured":"Willemse SB, Baak LC, Kuiken SD, van der Sluys VA, Lettinga KD, van der Meer JT, Depla AC, Tuynman H, van Nieuwkerk CM, Schinkel CJ, Kwa D, Reesink HW, van der Valk M. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat. 2016;23:950\u20134.","journal-title":"J Viral Hepat"},{"key":"1094_CR25","doi-asserted-by":"publisher","first-page":"e0170933","DOI":"10.1371\/journal.pone.0170933","volume":"12","author":"D Degr\u00e9","year":"2017","unstructured":"Degr\u00e9 D, Serst\u00e9 T, Lasser L, Delwaide J, Starkel P, Laleman W, Langlet P, Reynaert H, Bourgeois S, Vanwolleghem T, Negrin Dastis S, Gustot T, Geerts A, Van Steenkiste C, de Galocsy C, Lepida A, Orlent H, Moreno C. Sofosbuvir in combination with Simeprevir +\/\u2212 ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: a real-world experience from Belgium. PLoS One. 2017;12:e0170933.","journal-title":"PLoS One"},{"key":"1094_CR26","doi-asserted-by":"publisher","first-page":"e0168713","DOI":"10.1371\/journal.pone.0168713","volume":"12","author":"T Asselah","year":"2017","unstructured":"Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Crax\u00ed A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-week Simeprevir plus Peginterferon\/ribavirin (PR) regimen in treatment-Na\u00efve patients with hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment Virologic response. PLoS One. 2017;12:e0168713.","journal-title":"PLoS One"},{"key":"1094_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, Su F, Berry K. Effectiveness of Sofosbuvir, Ledipasvir\/Sofosbuvir, or Paritaprevir\/ritonavir\/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C in the veterans affairs National Health Care System. Gastroenterology. 2016;151:457\u201371.","journal-title":"Gastroenterology"},{"key":"1094_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.cgh.2017.02.020","volume":"15","author":"J Crespo","year":"2017","unstructured":"Crespo J, Calleja JL, Fern\u00e1ndez I, Sacristan B, Ruiz-Antor\u00e1n B, Ampuero J, Hern\u00e1ndez-Conde M, Garc\u00eda-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, S\u00e1ez-Royuela F, Arenas J, Rinc\u00f3n D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascu\u00e9s CA, Molina E, Moya AG, Moreno-Planas JM. Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol. 2017;15:945\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1094_CR29","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jvh.12708","volume":"24","author":"TM Welzel","year":"2017","unstructured":"Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, Berg T, Mauss S, Teuber G, Stein K, Deterding K, van B\u00f6mmel F, Heyne R, John C, Zimmermann T, Lutz T, Schott E, Hettinger J, Kleine H, K\u00f6nig B, H\u00fcppe D, Wedemeyer H. Real-world experience with the all-oral, interferon-free regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German hepatitis C registry. J Viral Hepat. 2017;24:840\u20139.","journal-title":"J Viral Hepat"},{"key":"1094_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/jvh.12637","volume":"24","author":"C Perell\u00f3","year":"2017","unstructured":"Perell\u00f3 C, Carri\u00f3n JA, Ruiz-Antor\u00e1n B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, Garc\u00eda-Samaniego J, Garc\u00eda-Paredes F, Fern\u00e1ndez I, Morillas RM, Rinc\u00f3n D, Porres JC, Prieto M, L\u00e1zaro R\u00edos M, Fern\u00e1ndez-Rodr\u00edguez C, Hermo JA, Rodr\u00edguez M, Herrero JI, Ruiz P, Fern\u00e1ndez JR, Mac\u00edas M, Pascasio JM, Moreno JM, Serra M\u00c1, Arenas J, Real Y, Jorquera F, Calleja JL. Spanish Collaborative Group for the Study of the Use of Hepatitis C Direct-Acting Drugs. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir \u00b1 dasabuvir \u00b1 ribavirin: An early access programme for Spanish patients with genotype 1\u20134 chronic hepatitis C virus infection. J Viral Hepat. 2017;24:226\u201337.","journal-title":"J Viral Hepat."},{"key":"1094_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S2468-1253(17)30048-1","volume":"2","author":"S Petta","year":"2017","unstructured":"Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Crax\u00ec A. ABACUS study group; AIFA team. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017;2:427\u201334.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1094_CR32","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/jvh.12722","volume":"24","author":"H Wedemeyer","year":"2017","unstructured":"Wedemeyer H, Crax\u00ed A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, Pangerl A, Zhang Z, Martinez M, Bao Y, Calleja JL. Real-world effectiveness of Ombitasvir\/Paritaprevir\/ritonavir \u00b1 Dasabuvir \u00b1 ribavirin in patients with HCV genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24:936\u201343.","journal-title":"J Viral Hepat"},{"key":"1094_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","volume":"152","author":"TE Komatsu","year":"2017","unstructured":"Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ, Harrington PR. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of Elbasvir and Grazoprevir. Gastroenterology. 2017;152:586\u201397.","journal-title":"Gastroenterology"},{"key":"1094_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/00365521.2017.1283439","volume":"52","author":"C Maria","year":"2017","unstructured":"Maria C, Michael S, Susanne C, Catarina S, Ola W. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse \u2013 a Swedish real life experience. Scand J Gastroenterol. 2017;52:585\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"1094_CR35","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1016\/j.jhep.2015.09.009","volume":"64","author":"C Hezode","year":"2016","unstructured":"Hezode C, Abergel A, Chas J, et al. Sustanined virologic response to daclatasvir and sofosbuvir with or without ribavirin, among patients in the French daclatasvir ATU programme infected with HCV genotypes 4,5,6. J Hepatol. 2016;64:S133\u201342 Available at: \n                    http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(16)01471-9\/abstract\n                    \n                  .","journal-title":"J Hepatol"},{"issue":"5","key":"1094_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MCG.0000000000000896","volume":"52","author":"MA Babatin","year":"2017","unstructured":"Babatin MA, Alghamdi AS, Albenmousa A, Alaseeri A, Aljarodi M, Albiladi H, Alsahafi A, Almugharbal M, Alothmani HS, Sanai FM, Bzeizi KI. Efficacy and safety of Simeprevir or Daclatasvir in combination with Sofosbuvir for the treatment of hepatitis C genotype 4 infection. J Clin Gastroenterol. 2017;52(5):452\u20137 [Epub ahead of print].","journal-title":"J Clin Gastroenterol"},{"key":"1094_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000454819","volume":"45","author":"S Abad","year":"2017","unstructured":"Abad S, Vega A, Hern\u00e1ndez E, M\u00e9rida E, de Sequera P, Albalate M, Mac\u00edas N, Milla M, L\u00f3pez-G\u00f3mez JM. Universal sustained viral response to the combination of Ombitasvir\/Paritaprevir\/ritonavir and Dasabuvir with\/without ribavirin in patients on hemodialysis infected with hepatitis C virus genotypes 1 and 4. Am J Nephrol. 2017;45:267\u201372.","journal-title":"Am J Nephrol"},{"key":"1094_CR38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.ajkd.2017.01.037","volume":"70","author":"FR Ponziani","year":"2017","unstructured":"Ponziani FR, Siciliano M, Lionetti R, Pasquazzi C, Gianserra L, D'Offizi G, Gasbarrini A, Pompili M. Effectiveness of Paritaprevir\/ritonavir\/Ombitasvir\/Dasabuvir in hemodialysis patients with hepatitis C virus infection and advanced liver fibrosis: case reports. Am J Kidney Dis. 2017;70:297\u2013300.","journal-title":"Am J Kidney Dis"},{"key":"1094_CR39","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jhep.2018.03.010","volume":"68","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty MI, Ramadan M. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol. 2018;68:1313\u20135.","journal-title":"J Hepatol"},{"issue":"5","key":"1094_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s10620-018-5005-8","volume":"63","author":"A Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M. Retreatment efficacy of Sofosbuvir\/Ombitasvir\/Paritaprevir\/ritonavir\u2009+\u2009ribavirin for hepatitis C virus genotype 4 patients. Dig Dis Sci. 2018;63(5):1341\u20137.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1094_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s12072-018-9868-8","volume":"12","author":"Adel Abdel-Moneim","year":"2018","unstructured":"Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M. Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Hepatol Int. 2018;12(4):348\u201355.","journal-title":"Hepatology International"},{"key":"1094_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263\u201371.","journal-title":"J Hepatol"},{"key":"1094_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","volume":"30","author":"N Antaki","year":"2010","unstructured":"Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 2010;30:342\u201355.","journal-title":"Liver Int"},{"key":"1094_CR44","unstructured":"American Association for the Study of Liver Diseases (AALSD). HCV Guidance: Recomendations for Testing, Managing and Treating Hepatitis C. \n                    https:\/\/www.hcvguidelines.org\n                    \n                  . Accessed on 05 March 2018."},{"key":"1094_CR45","unstructured":"European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2016. \n                    http:\/\/www.easl.eu\/medias\/cpg\/HCV2016\/English-report.pdf\n                    \n                  . Accessed on 05 March 2018."},{"key":"1094_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns M, Samuel D, Gane EJ, Mutimer D, Mc Caughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, M\u00fcllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, JG MH, Dufour JF, Van Vlierberghe H, van Hoek B. Forns X; SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685\u201397.","journal-title":"Lancet Infect Dis."}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-018-1094-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1094-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T19:09:19Z","timestamp":1574363359000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-1094-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-1094-4","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,22]]},"assertion":[{"value":"22 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"180"}}